CAREDX, INC. (NASDAQ:CDNA) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
On June13, 2017, CareDx, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the “Meeting”). Of the 21,421,016 shares of common stock outstanding as of May15, 2017, the record date for the Meeting, 14,679,329 shares were represented at the meeting in person or by proxy, constituting 68.53% of the outstanding shares entitled to vote and constituting a quorum for the transaction of business.
At the Meeting, the Company’s stockholders considered three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May30, 2017:
Set forth below is a brief description of each matter voted upon at the Meeting and the voting results with respect to each matter.
Proposal No.1 – To elect two Class III directors to serve until the 2020 annual meeting of stockholders or until their successors are duly elected and qualified.
|
Nominee |
Votes For | VotesWithheld | BrokerNon-Votes |
|
Michael D. Goldberg |
7,548,202 | 451,014 | 6,680,113 |
|
Peter Maag, Ph.D. |
7,515,676 | 483,540 | 6,680,113 |
Proposal No.2 – To ratify the appointment of Ernst& Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December31, 2017.
|
Votes For |
VotesAgainst |
Abstentions |
BrokerNon-Votes |
| 14,293,728 | 287,272 | 98,329 |
Proposal No.3 – To approve the issuance of shares of the Company’s common stock upon the conversion or redemption of the Company’s 9.5% Original Issue Discount Senior Secured Debentures due February28, 2020 without the need for any limitation or cap on issuances as required by and in accordance with NASDAQ Listing Rule 5635.
|
Votes For |
VotesAgainst |
Abstentions |
BrokerNon-Votes |
| 7,965,731 | 33,485 | 6,680,113 |
About CAREDX, INC. (NASDAQ:CDNA)
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.